Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
1. Claseprubart shows significant efficacy in treating Myasthenia Gravis. 2. Both 300mg and 600mg doses achieved clinical improvements by Week 13. 3. Phase 3 trials for Claseprubart are expected to begin in 2026. 4. No serious safety issues reported; favorable side effect profile noted. 5. Investor conference detailing results scheduled for September 8, 2025.